In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The CoNNCT Initiative: Accelerating Novel Combinations For Cancer

Executive Summary

Combination therapies are the cornerstone of oncology, but the development model has been slow to shift to early testing of combinations of investigational drugs. The CoNNCT initiative aims to accelerate clinical testing of novel-novel combinations, and in doing so provide benefits for biopharma, clinicians and the cancer patients they serve.

Advertisement

Related Content

Key Trends In Immuno-Oncology Dealmaking
Revisiting Cell Screening To Find New Cancer Drug Combos

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV004501

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel